Date | Time | Source | Headline | Symbol | Company |
11/17/2006 | 4:02PM | Business Wire | Gilead Sciences Completes Acquisition of Myogen | NASDAQ:MYOG | Myogen |
11/06/2006 | 8:00AM | Business Wire | Darusentan Data to Be Presented at AHA 2006 -- Chicago | NASDAQ:MYOG | Myogen |
10/17/2006 | 4:00PM | Business Wire | Darusentan Data to Be Presented at ISH 2006 -- Fukuoka, Japan | NASDAQ:MYOG | Myogen |
10/10/2006 | 8:00AM | Business Wire | Four Ambrisentan Studies to Be Presented at Chest 2006 -- Salt Lake City | NASDAQ:MYOG | Myogen |
10/02/2006 | 12:11PM | PR Newswire (US) | Seven Summits Research Releases Comments on GOOG, ABX, HET, CBS, and MYOG | NASDAQ:MYOG | Myogen |
10/02/2006 | 7:00AM | Business Wire | Gilead Sciences to Acquire Myogen, Inc. for $2.5 Billion | NASDAQ:MYOG | Myogen |
09/20/2006 | 8:30AM | Business Wire | Myogen to Present at the UBS Global Life Sciences Conference | NASDAQ:MYOG | Myogen |
09/07/2006 | 8:00AM | Business Wire | Myogen Initiates Open-Label Phase 3 Clinical Trial of Ambrisentan in Patients with Pulmonary Hypertension | NASDAQ:MYOG | Myogen |
09/06/2006 | 8:00AM | Business Wire | The American Lung Association and Myogen Announce Pulmonary Arterial Hypertension Educational Partnership | NASDAQ:MYOG | Myogen |
08/07/2006 | 4:00PM | Business Wire | Myogen Reports 2006 Second Quarter Results | NASDAQ:MYOG | Myogen |
07/25/2006 | 7:45AM | Business Wire | Myogen to Announce 2006 Second Quarter Results on August 7, 2006 | NASDAQ:MYOG | Myogen |
07/11/2006 | 8:30AM | Business Wire | Myogen Announces Extension of Drug Discovery Collaboration | NASDAQ:MYOG | Myogen |
06/08/2006 | 7:30AM | Business Wire | Myogen to Present at the Goldman Sachs Global Healthcare Conference | NASDAQ:MYOG | Myogen |
06/05/2006 | 8:01AM | Business Wire | Myogen Initiates Phase 3 Clinical Trial of Darusentan in Patients with Resistant Hypertension | NASDAQ:MYOG | Myogen |
05/24/2006 | 6:30AM | Business Wire | Ambrisentan Phase 3 ARIES-2 PAH Data Presented At ATS 2006 -- San Diego; Significant Improvement in Six-Minute Walk Distance an | NASDAQ:MYOG | Myogen |
05/08/2006 | 7:00AM | Business Wire | Myogen Reports 2006 First Quarter Results | NASDAQ:MYOG | Myogen |
05/03/2006 | 4:00PM | Business Wire | Myogen Reports Results for the Integrated Analysis of ARIES-1 and ARIES-2 Pivotal Trials of Ambrisentan in Pulmonary Arterial H | NASDAQ:MYOG | Myogen |
04/21/2006 | 7:00AM | Business Wire | Myogen to Announce 2006 First Quarter Results on May 8, 2006 | NASDAQ:MYOG | Myogen |
04/19/2006 | 4:00PM | Business Wire | Myogen to Present at the Leerink Swann Vascular Modlulation Conference | NASDAQ:MYOG | Myogen |
04/10/2006 | 12:36PM | PR Newswire (US) | Seven Summits Research releases comments on AAPL, EBAY, HAL, MYOG, and URBN | NASDAQ:MYOG | Myogen |
04/10/2006 | 7:00AM | Business Wire | Myogen Reports Positive Top Line Results for Second Ambrisentan Pivotal Phase 3 Trial in Pulmonary Arterial Hypertension; ARIES | NASDAQ:MYOG | Myogen |
03/09/2006 | 10:57AM | PR Newswire (US) | Seven Summits Research Releases Comments on MRVL, DELL, SGP, GENZ, and MYOG | NASDAQ:MYOG | Myogen |
03/09/2006 | 8:00AM | Business Wire | Ambrisentan Receives FDA Fast Track Designation for PAH Development | NASDAQ:MYOG | Myogen |
03/06/2006 | 4:10PM | Business Wire | Myogen Reports 2005 Results | NASDAQ:MYOG | Myogen |
03/02/2006 | 8:00AM | Business Wire | Ambrisentan ARIES-2 Data to Be Presented at ATS 2006 -- San Diego | NASDAQ:MYOG | Myogen |
02/28/2006 | 4:00PM | Business Wire | Myogen to Present at the Citigroup Small & Mid-Cap Conference | NASDAQ:MYOG | Myogen |
02/13/2006 | 8:30AM | PR Newswire (US) | Myogen Reports Positive Top Line Results for Ambrisentan LFT Rescue Study In Pulmonary Arterial Hypertension | NASDAQ:MYOG | Myogen |
02/06/2006 | 10:12AM | PR Newswire (US) | NASDAQ Hosts First-Ever Investor Conference in London for Small Cap Companies | NASDAQ:MYOG | |
02/06/2006 | 8:00AM | PR Newswire (US) | Myogen to Announce 2005 Results on March 6, 2006 | NASDAQ:MYOG | Myogen |
02/02/2006 | 4:30PM | PR Newswire (US) | Myogen Announces Sale of Myogen GmbH | NASDAQ:MYOG | Myogen |